

1 Induction of trained immunity by influenza vaccination - impact on COVID-19

2

3 Priya A. Debisarun^{1,9}, Katharina L. Gössling^{2,9}, Ozlem Bulut¹, Gizem Kilic¹, Martijn Zoodsma^{3,4},
4 Zhaoli Liu^{3,4}, Marina Oldenburg², Nadine Rüchel², Bowen Zhang^{3,4}, Cheng-Jian Xu^{1,3,4}, Patrick
5 Struycken⁵, Valerie A.C.M. Koeken^{1,3,4}, Jorge Domínguez-Andrés¹, Simone J.C.F.M. Moorlag¹,
6 Esther Taks¹, Philipp N. Ostermann⁶, Lisa Müller⁶, Heiner Schaal⁶, Ortwin Adams⁶, Arndt
7 Borkhardt², Jaap ten Oever¹, Reinout van Crevel¹, Yang Li^{3,4}, Mihai G. Netea^{1,7,8*}

8

9 ¹ Department of Internal Medicine, Radboud University Medical Center, 6525GA, Nijmegen,
10 Netherlands

11 ² Department for Pediatric Oncology, Hematology and Clinical Immunology, University Hospital
12 Duesseldorf, Medical Faculty, Heinrich Heine University Duesseldorf, 40225, Dusseldorf, Germany

13 ³ Department of Computational Biology for Individualised Infection Medicine, Centre for Individualised
14 Infection Medicine (CiIM), a joint venture between the Helmholtz-Centre for Infection Research (HZI)
15 and the Hannover Medical School (MHH), 30625, Hannover, Germany

16 ⁴TWINCORE, a joint venture between the Helmholtz-Centre for Infection Research (HZI) and the
17 Hannover Medical School (MHH), 30625, Hannover, Germany

18 ⁵Department of Occupational Health & Safety, and Environmental Service, Radboud University
19 Medical Center, 6525EX, Nijmegen, Netherlands

20 ⁶Institute of Virology, University Hospital Duesseldorf, Medical Faculty, Heinrich Heine University
21 Duesseldorf, 40225, Dusseldorf, Germany

22 ⁷Human Genomics Laboratory, Craiova University of Medicine and Pharmacy, 200349, Craiova,
23 Romania.

24 ⁸ Department for Immunology & Metabolism, Life and Medical Sciences Institute (LIMES), University of
25 Bonn, 53115, Bonn, Germany

26 ⁹These authors contributed equally.

27

28 *Correspondence: mihai.netea@radboudumc.nl

29 Mihai G. Netea, M.D., Ph.D.

30 Department of Medicine (463)

31 Radboud University Nijmegen Medical Center

32 Geert Grooteplein Zuid 8, 6525 GA Nijmegen, The Netherlands

33 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**
Tel: +31-24-3618819; E-mail: mihai.netea@radboudumc.nl

34 **ABSTRACT**

35

36 Non-specific protective effects of certain vaccines have been reported, and long-term boosting of innate
37 immunity, termed *trained immunity*, has been proposed as one of the mechanisms mediating these
38 effects. Several epidemiological studies suggested cross-protection between influenza vaccination and
39 COVID-19. In a large academic Dutch hospital, we found that SARS-CoV-2 infection was less common
40 among employees who had received a previous influenza vaccination: relative risk reductions of 37%
41 and 49% were observed following influenza vaccination during the first and second COVID-19 waves,
42 respectively. The quadrivalent inactivated influenza vaccine induced a trained immunity program that
43 boosted innate immune responses against various viral stimuli and fine-tuned the anti-SARS-CoV-2
44 response, which may result in better protection against COVID-19. Influenza vaccination led to
45 transcriptional reprogramming of monocytes and reduced systemic inflammation. These epidemiological
46 and immunological data argue for potential benefits of influenza vaccination against COVID-19, and
47 future randomized trials are warranted to test this possibility.

48

49 **Keywords:** Influenza vaccine, COVID-19, SARS-CoV-2, trained immunity, cytokines, vaccination

50 1. INTRODUCTION

51 As of May 2021, over 150 million cases and 3.1 million deaths due to the novel coronavirus disease
52 COVID-19 have been reported (1). COVID-19 is caused by severe acute respiratory syndrome
53 coronavirus 2 (SARS-CoV-2). While in the majority of cases the virus causes mild symptoms that resolve
54 spontaneously, in the elderly or patients with underlying co-morbidities, the disease is often severe and
55 potentially lethal (2). Due to the rapid spread and high clinical and socio-economic burden of COVID-
56 19, sustained efforts have been made to develop preventive and therapeutic strategies (3, 4). Several
57 effective anti-COVID-19 vaccines have been designed and successfully tested, with almost 1 billion
58 vaccine doses already administered (1). However, vaccine supply is still not able to ensure the global
59 needs, with many countries facing challenges in ensuring access to enough COVID-19 vaccines (5). An
60 additional challenge is the emergence of new SARS-CoV-2 variants which are on the one hand more
61 infective, and on the other hand can display vaccine escape (6).

62 Due to the absence of specific COVID-19 vaccines in the beginning of the pandemic, as well as the
63 current challenges posed by limited vaccine supply and emergence of new virus strains, vaccination
64 strategies using already available vaccines that can protect against a broad array of pathogens has
65 been proposed as 'bridge vaccination' (7). The potential interaction between vaccines and infections
66 other than their target disease has attracted a lot of attention lately. It has been demonstrated that certain
67 vaccines, such as Bacillus Calmette-Guérin (BCG), measles-containing vaccines, or oral polio vaccine,
68 have strong non-specific protective effects through long-term reprogramming of innate immunity, a
69 process called *trained immunity* (8). In line with this, several recent studies suggested a potential link
70 between influenza vaccination and decreased COVID-19 incidence and severity (9-12). This suggests
71 that influenza vaccination may potentially convey partial protection against COVID-19, and this potential
72 beneficial effect needs to be investigated.

73 In this study, we assessed the association between influenza vaccination and COVID-19 incidence
74 during the first two waves of the pandemic in the Netherlands, among employees of the Radboud
75 University Medical Center (Radboudumc), a large academic hospital. In addition, as possible
76 mechanisms of action, we investigated the induction of trained immunity and the impact on systemic
77 inflammation by the influenza vaccine used in the 2020 autumn season in 28 healthy adult volunteers.

78

79 **2. RESULTS**

80 **2.1. Quadrivalent inactivated influenza vaccination is associated with lower COVID-19 incidence**

81 To investigate the effect of influenza vaccination on COVID-19 incidence, we compared the incidence
 82 of COVID-19 cases, validated by SARS-CoV-2 PCR, among hospital workers who were either
 83 vaccinated or not against influenza.

84 As of June 1st, 2020, at the end of the first COVID-19 wave in the Netherlands, Radboudumc had 6856
 85 employees working in the clinical departments with direct patient contact (Table 1). The total influenza
 86 vaccine coverage rate (VCR) in the hospital for that season (autumn 2019) was 53% (3655/6856).
 87 Among these, 184 were documented to have contracted SARS-CoV-2 PCR-positive COVID-19. 42% of
 88 SARS-CoV-2 positive individuals during the first wave (77/184) had received an influenza vaccination
 89 in the preceding flu season, as opposed to 54% (3578/6672) of SARS-CoV-2 negative employees:
 90 3.34% of the individuals who were not vaccinated against influenza had COVID-19, compared to 2.11%
 91 of the vaccinated employees (RR=0.63, 95% CI, 0.47-0.84, P=0.0016).

92

93 **Table 1: COVID-19 incidence among influenza vaccinated and unvaccinated employees of**
 94 **Radboud University Medical Center in the first two waves of the pandemic.** First wave: March -
 95 June 2020, second wave: November 2020 - January 2021. Influenza vaccinations in autumn of 2019
 96 and autumn of 2020 were considered for calculations regarding the first and the second COVID-19
 97 waves, respectively.

98

		First wave				Second wave			
		SARS-CoV-2 negative	SARS-CoV-2 positive	Total	SARS-CoV-2 incidence	SARS-CoV-2 negative	SARS-CoV-2 positive	Total	SARS-CoV-2 incidence
Influenza vaccination	No	3094	107	3201	3.34%	6120	250	6370	3.92%
	Yes	3578	77	3655	2.11%	4438	91	4529	2.00%
	Total	6672	184	6856	2.68%	10558	341	10899	3.13%

99

100

101 A lower incidence of SARS-CoV-2 positivity among vaccinated individuals was also reported during the
102 second wave (Table 1), when data for the total number of 10899 Radboudumc employees became
103 available. The hospital's total influenza vaccination coverage rate during the 2020/2021 influenza
104 season was 42% (4529/10899). 91 of the 341 SARS-CoV-2 positive employees (27%) were vaccinated
105 against influenza in the autumn 2020. The COVID-19 incidence during the second wave was 3.92%
106 among unvaccinated employees and 2.00% for vaccinated employees (RR of 0.51, 95% CI 0.40-0.65,
107 $P < 0.0001$).


108 Our results indicate that influenza vaccination was significantly associated with lower COVID-19
109 incidence among hospital employees during the first two waves of the pandemic.

110

111 **2.2. Influenza vaccination induces long-term transcriptional reprogramming**

112 To assess a possible induction of trained immunity upon influenza vaccination as the underlying
113 mechanism of protection against SARS-CoV-2, a proof-of-principle study to assess the non-specific
114 immunological effects of the influenza vaccination was performed in 28 healthy individuals. Participants
115 received an influenza vaccine (Influvac Tetra), and blood was collected 1 week before and 6 weeks after
116 vaccination. The study design is summarized in Figure 1.

117



118

119 **Figure 1: Summary of the clinical study investigating the effects of an influenza vaccine on**
120 **trained immunity.** Blood was collected 1 week before and 6 weeks after the influenza vaccination from
121 28 participants. PBMC stimulation, quantification of plasma proteins, and single-cell RNA sequencing
122 were performed.


123

124 Long-term transcriptional reprogramming of innate immune cells is a hallmark of the induction of trained
125 immunity. We performed single-cell RNA-sequencing (scRNA-seq) on the peripheral blood mononuclear
126 cells (PBMCs) collected from 10 individuals before and after influenza vaccination. In total, 10,785 cells
127 before and 14,777 cells after vaccination were collected and clustered into 10 subsets, which were
128 annotated by their marker gene expression as CD14+ monocytes, CD16+ monocytes, CD4+ naïve T
129 cells, memory CD4+ T cells, CD8+ T cells, natural killer cells, B cells, dendritic cells and megakaryocytes
130 (S1A Figure). Immune cell counts were similar after vaccination compared to before (S1B Figure).

131 While vaccination induced transcriptomic changes in both lymphoid and myeloid cells, some of the most
132 prominent transcriptional changes were observed in CD14+ monocytes (Figure 2A). 136 genes were

133 differentially expressed in CD14+ monocytes, of which 103 were upregulated and 33 were
 134 downregulated, comparable with the changes observed in CD4+ naïve T cells (138 differentially
 135 expressed genes (DEGs), 105 of them upregulated and 23 downregulated) (Figure 2A and C). Among
 136 the most differentially expressed genes, myeloid cell nuclear differentiation antigen (*MNDA*) and
 137 cathepsin S (*CTSS*) were strongly upregulated in CD14+ monocytes after influenza vaccination (Figure
 138 2A-B). Interestingly, three long non-coding RNAs (lncRNAs, the nuclear paraspeckle assembly
 139 transcript 1 (*NEAT1*), metastasis associated lung adenocarcinoma transcript 1 (*MALAT1* or *NEAT2*),
 140 and splicing factor proline and glutamine rich *SFPQ*), and genes related to the NFK β signaling pathway
 141 (NFKB Inhibitor Alpha (*NFKBIA*), and *JUN*), were downregulated in CD14+ monocytes after vaccination
 142 (Figure 2A). Unlike the downregulation in monocytes, *JUN* was upregulated in CD4+ T cells after the
 143 vaccination (Figure 2C).

144



145

146 **Figure 2: Transcriptomic changes induced by influenza vaccination on a single cell level. A.**

147 Volcano plot depicting the upregulated and downregulated genes in CD14+ monocytes 6 weeks after

148 influenza vaccination. Red dots show upregulation, while blue dots show downregulation. B. Violin plots

149 showing the expression levels of *MNDA* and *CTSS* before and after vaccination in CD14+ monocytes.

150 C. Volcano plot depicting the upregulated and downregulated genes in CD4+ naïve T cells 6 weeks after

151 influenza vaccination. Significantly changing top 15 genes were labeled on the volcano plots. D.
152 Pathway analysis of genes up-regulated or down-regulated by influenza vaccination.

153

154 Pathway enrichment analyses revealed that several pathways important for host defense against
155 COVID-19 were upregulated by influenza vaccination: COVID-19 pathway, antigen processing and
156 presentation pathway, while mRNA splicing, histone H3 deacetylation and IL-17 pathways were
157 downregulated in CD14+ monocytes (Figure 2D). On the other hand, naïve CD4+ T cells exhibited
158 upregulation in translation, protein localization, and viral gene expression and downregulation in
159 lymphocyte differentiation and NFκB signaling (S2 Figure, upper panel). Lastly, type I IFN signaling and
160 antigen presentation pathways were among the upregulated pathways in memory CD4+ T cells, while
161 mRNA splicing was downregulated (S2 Figure, lower panel).


162 Together, the data show that influenza vaccination induces extensive transcriptomic changes in immune
163 cells, including CD14+ monocytes.

164

165 **2.3. Influenza vaccination downregulates systemic inflammation**

166 Dysregulated inflammatory responses play an important role in the pathogenesis of COVID-19, and we
167 wanted to assess whether influenza vaccination impacts systemic inflammatory reaction. 1472 proteins
168 in the plasma of 10 participants were measured with the Olink proteomics platform before and after
169 vaccination. 368 of the proteins belonged to a panel of inflammatory biomarkers. Principal component
170 analysis performed with these 368 proteins revealed a significant difference between samples before
171 and after influenza vaccination, with a vast majority of inflammatory biomarkers being strongly down-
172 regulated after vaccination (Figure 3A). TNF receptor superfamily member 14 (TNFRSF14), interleukin-
173 1 receptor-associated kinase 1 (IRAK1), and mitogen-activated protein kinase kinase 6 (MAP2K6) were
174 among the proteins that contributed the most to that difference (S3 Figure). Wilcoxon paired signed-
175 rank test identified one upregulated and 82 downregulated proteins in the inflammation panel after
176 influenza vaccination ($P<0.05$; Figure 3B). The only upregulated protein, polypeptide N-
177 acetylgalactosaminyltransferase 3 (GALNT3), is involved in protein glycosylation and important for
178 oligosaccharide biosynthesis. The 82 downregulated proteins include many chemokines (Figure 3B and

179 C), proteins related to tumor necrosis factor (TNF) signaling such as TNF receptor-associated factor 4
 180 (TRAF4) and TNFRSF14, interleukin 1 β (IL-1 β), IRAK1, IRAK4, and MAP2K6.
 181



182

183 **Figure 3: Influenza vaccination downregulates circulating inflammatory proteins.**

184 A. Principal component analysis (PCA) of circulating proteins belonging to 10 participants before and
 185 after vaccination. The mean difference between before and after in PC1 was calculated by Wilcoxon
 186 signed-rank test. B. Volcano plot depicting the fold changes after influenza vaccination. Red dots show
 187 significantly changing proteins. C. Selected chemokines whose abundances significantly decrease after
 188 the vaccination. Differences between protein expressions before and after influenza vaccination were
 189 analyzed using the Wilcoxon signed-rank test, n=10. NPX: Normalized protein expression. *p<0.05,
 190 **p<0.01.

191 Additionally, pathway enrichment analysis was performed with all 283 downregulated proteins, also
 192 including proteins from oncology, neurology and cardiometabolic Olink panels (S4 Figure). Noticeable
 193 pathways downregulated by influenza vaccination include apoptotic signaling, myeloid cell activation,
 194 leukocyte degranulation, and DNA damage response.

195 Overall, these data demonstrate that influenza vaccination is associated with lower systemic
196 inflammation and downregulation of several inflammatory and apoptotic pathways.


197

198 **2.4. Influenza vaccination influences cytokine production capacity**

199 Next, we investigated whether the influenza vaccine could modulate cytokine responses after stimulation
200 with specific or heterologous ligands and induce trained immunity. Freshly isolated PBMCs before and
201 after influenza vaccination of the volunteers were stimulated *ex vivo* with heat-inactivated SARS-CoV-
202 2, heat-inactivated Influenza H1N1, poly(I:C) (TLR3 ligand), and R848 (TLR7/8 ligand).

203 Influenza vaccination led to significantly higher TNF α production upon Influenza and poly(I:C)
204 stimulation (Figure 4A). On the other hand, IL-6 production was strikingly lower against SARS-CoV-2 6
205 six weeks after vaccination (Figure 4B). Similar to TNF α , poly(I:C) induced higher IL-6 secretion from
206 PBMCs 6 weeks after vaccination, compared to the stimulation one week before the vaccine
207 administration.

208



209

210 **Figure 4: Ex vivo cytokine responses of the individuals before and after influenza vaccination.**

211 PBMCs were stimulated with heat-killed Influenza H1N1 (California strain), heat-killed SARS-CoV-2,

212 poly I:C, and R848 for 24 hours. A. TNF α , B. IL-6, C. IL-1 β , D. IL-1RA, and E. IL-12 responses were

213 quantified. SARS-CoV-2 and Influenza stimulations did not lead to detectable levels of IL-12. Wilcoxon

214 signed-rank test was performed to compare the differences in cytokine production between before and

215 after influenza vaccination. Light blue dots represent the cytokine values before vaccination, while dark

216 blue dots show after vaccination. n=28 *p<0.05, **p<0.01, ****p<0,0001.


217

218 We also quantified the two major cytokines of the IL-1 pathway, IL-1 β and IL-1Ra, following the exposure
219 of PBMCs with viral stimuli. SARS-CoV-2-induced IL-1 β response was significantly reduced after the
220 influenza vaccination, while poly(I:C) resulted in higher IL-1 β production (Figure 4C). IL-1 β production
221 following SARS-CoV-2 stimulation was below detection limit in 10 individuals before vaccination, and in
222 15 individuals after influenza vaccination. In contrast, SARS-CoV-2 stimulation induced higher IL-1Ra
223 production from PBMCs 6 weeks after the influenza vaccination, compared to the baseline release
224 before vaccination (Figure 4D). R848 induced similar concentrations of the innate immune cytokines
225 before and after vaccination. However, a significantly higher IL-12 secretion was observed after poly(I:C)
226 and R848 stimulation (Figure 4E). Of note, SARS-CoV-2 and Influenza did not lead to detectable levels
227 of IL-12 in PBMCs.

228 T cell-derived cytokines, IFN γ , IL-17, and IL-22 produced by PBMCs upon heat-killed Influenza
229 stimulation were similar before and after vaccination (S5 Figure).

230 Lastly, we investigated whether baseline systemic inflammatory status is associated with the change of
231 anti-SARS-CoV-2 responses upon influenza vaccination. Out of 82 inflammatory mediators
232 downregulated by vaccination, 26 were significantly correlated with the production of at least one
233 cytokine (Figure 5A). An overwhelming majority of them were positively correlated with the increased
234 ratio in the production of the anti-inflammatory cytokines IL-1Ra and IL-10 after vaccination. Inhibitor of
235 NF- κ B kinase regulatory subunit gamma (IKBKG) and TRAF2 were positively correlated with the
236 increase in IL-1 β induction, while hepatocyte growth factor (HGF) with IL-6 induction (Figure 5A and B).
237 Tripartite motif-containing 5 (TRIM5), AXIN1, and galectin 9 (LGALS9) were negatively correlated with
238 the change in TNF α production capacity. Baseline concentrations of GALNT3, the only upregulated
239 protein that belonged to the inflammation panel, were negatively correlated with the induction of anti-
240 SARS-CoV-2 IL-6 response (Figure 5C).

241



242

243 **Figure 5: Correlation of ex vivo anti-SARS-CoV-2 responses with circulating inflammatory**
 244 **mediators that are significantly altered by influenza vaccination.** A. Heatmap depicting the baseline
 245 (before vaccination) levels of inflammatory mediators that were downregulated by influenza vaccination
 246 and are significantly correlated with the induction of cytokines upon SARS-CoV-2 stimulation before vs.
 247 after vaccination. Red indicates positive correlation, and blue indicates negative correlation. B. Selected
 248 circulating protein and cytokine pairs that are significantly correlated. C. Correlation of circulating
 249 proteins that were upregulated by influenza vaccination with anti-SARS-CoV-2 cytokine responses, and
 250 dot plot depicting the association of baseline GALNT3 levels and induction IL-6 against SARS-CoV-2
 251 after vaccination. r: Spearman's correlation coefficient. *p<0.05, **p<0.01, ***p<0,001.

252

253 Collectively, the data indicate that seasonal influenza vaccination can induce a more robust innate
 254 immune response against viral stimuli such as poly(I:C) and R848. Interestingly, after SARS-CoV-2
 255 stimulation, the trained immunity program induced by influenza vaccination is characterized by lower
 256 pro-inflammatory and higher anti-inflammatory cytokine production. Furthermore, higher baseline
 257 inflammation was correlated with a more anti-inflammatory response against SARS-CoV-2 after
 258 vaccination.

259 3. DISCUSSION

260 In this study, we present epidemiological and immunological evidence that quadrivalent inactivated
261 influenza vaccination influences the response to and the incidence of SARS-CoV-2 infection. Relative
262 risk reduction for a COVID-19 positive diagnosis in individuals vaccinated against influenza was 37%
263 and 49% during the first and second COVID-19 waves, respectively, suggesting a protective effect of
264 influenza vaccination against infection with SARS-CoV-2. In addition, we found improved
265 responsiveness of immune cells to heterologous viral stimuli after influenza vaccination, arguing for
266 changes in innate immune responses characteristic of a trained immunity program. Moreover, influenza
267 vaccination modulated the responses against SARS-CoV-2, reducing IL-1 β and IL-6 production while
268 enhancing IL-1Ra release.

269 Our observation of reduced incidence of COVID-19 in the employees of a Dutch academic hospital is in
270 line with several recent epidemiological studies (S1 Table). Despite a few reports of a positive
271 association between influenza vaccine coverage and COVID-19 incidence and mortality (13, 14), most
272 studies from different countries have revealed a negative association between influenza vaccination and
273 COVID-19-related hospitalizations, ICU admissions, and mortality (10, 15-20). The strength of
274 epidemiological observations should be interpreted with caution due to the inherent possibility of bias in
275 observational trials. Information on confounding factors and effect modifiers can be missing, and
276 correction for confounders is sometimes not possible, causing over- or underestimation of outcomes.
277 The healthy vaccinee bias could also play a role in the overestimation of the positive effect of a vaccine:
278 individuals willing to be vaccinated against influenza may be also those more likely to respect the
279 personal protection rules against COVID-19 infection. However, an important argument that influenza
280 vaccination could truly exert protective effects against COVID-19 comes from a Brazilian study showing
281 negative correlations between influenza vaccine and COVID-19 mortality, need of ICU treatment, and
282 invasive respiratory support (18). Correction for comorbidities, several sociodemographic factors, and
283 healthcare facilities uphold the conclusions of this study, and these effects on disease severity in
284 individuals who already contracted COVID-19 cannot be explained by the healthy vaccinee bias.

285 It has been hypothesized that trained immunity might be an important mechanism underlying these
286 beneficial heterologous effects of vaccines (8). The most extensively studied vaccine that induces
287 trained immunity is BCG, which is currently being examined for its putative protective effects against

288 COVID-19 duration and severity in several clinical trials (NCT04328441, NCT04348370, NCT04327206,
289 NL8609). Although this property is usually assigned to live vaccines (21), whether inactivated influenza
290 vaccination can also induce trained immunity was not known. Here, we found that Influvac Tetra indeed
291 induces a transcriptional and functional reprogramming of innate immune cells 6 weeks after the
292 vaccination, modulating cytokine responses upon viral challenge with unrelated stimuli.

293 Single-cell RNA sequencing shows that transcriptional programs of both CD14⁺ monocytes and CD4⁺
294 T cells were considerably altered by the seasonal influenza vaccination. Among the most upregulated
295 genes in monocytes, *MNDA* is an interferon-inducible gene, known to increase in monocytes upon IFN α
296 exposure (22), while Cathepsin S (*CTSS*) participates in the MHC II-dependent presentation of antigens
297 (23). A similar protein, Cathepsin L, is shown to be critical for SARS-CoV-2 entry through endocytosis
298 (24). By enhancing the uptake, processing, and presentation of SARS-CoV-2 antigens, upregulation of
299 *CTSS* might be beneficial to induce the anti-viral immune response. Moreover, *MNDA* is shown to
300 restrict HIV-1 transcription and replication in human macrophages (25), and although not yet explored,
301 similar anti-viral effects may be envisaged against SARS-CoV-2.

302 Three of the most significantly downregulated genes in monocytes, *NEAT1*, *MALAT1* (*NEAT2*), and
303 *SFPQ*, contribute to inflammatory responses. Among them, *NEAT1* is associated with anti-viral
304 immunity, IL-8, and type I IFN production (26), while *MALAT1* induces pro-inflammatory cytokine
305 production (27). In contrast, *SFPQ* blocks *NEAT1* activity by binding to it (26). Similarly, *JUN* and
306 *NFKBIA*, which are both downregulated in CD14⁺ monocytes, oppose each other: JUN is a part of AP-
307 1 transcription factor complex stimulating cytokine production (28), while IKBA coded by *NFKBIA*
308 functions to inhibit NF κ B signaling, hence inflammatory response (29). Upregulation of JUN and FOS
309 that form AP-1 together in both CD4⁺ naïve and memory cells might contribute to improved anti-SARS-
310 CoV-2 T cell response. On the other hand, their downregulation in monocytes might be the underlying
311 mechanism of lower IL-6 and IL-1 β production observed after stimulation of immune cells of vaccinated
312 individuals with SARS-CoV-2. These data demonstrates that influenza vaccination induces a fine-tuning
313 of the cytokine production to viral stimulation, that could positively influence a balanced inflammatory
314 reaction during infection.

315 Previously, our group showed that the BCG vaccine reduces systemic inflammation, and baseline
316 inflammation is linked with trained immunity (30). In this study, plasma proteomic analyses revealed that

317 influenza vaccination also reduced the level of the systemic inflammation status, similarly to BCG. Only
318 GALNT3 was significantly more abundant in the circulation of vaccinated individuals. GALNT3 is known
319 to be upregulated by Influenza A infection, leading to mucin production and affecting virus replication
320 (31). Of note, GALNT3 levels were correlated with lower IL-6 response upon SARS-CoV-2 stimulation
321 after influenza vaccination, possibly contributing to the beneficial effects of the vaccine. On the other
322 hand, 82 proteins related to chemotaxis, apoptosis, and TLR signaling pathways were significantly
323 downregulated by vaccination. Caspases CASP3, CASP8, CASP10, and FAS associated death domain
324 (FADD) are important for apoptosis which is a pathway downregulated upon influenza vaccination (S4
325 Figure). SARS-CoV-2 was shown to induce cell death via activation of caspase-8, which eventually
326 leads to lung damage (32). Therefore, a lower abundance of the apoptotic proteins in the circulation
327 could contribute to the protection against SARS-CoV-2-related damage.

328 Systemic low-grade inflammation is associated with poor vaccine and immune responses (33). This is
329 in line with the results of this study demonstrating that reduced systemic inflammation induced by
330 influenza vaccination is subsequently associated with a higher pro-inflammatory cytokine production
331 against viral stimuli *in vitro*, such as Influenza and poly(I:C). In addition, influenza vaccination was
332 followed by a modified pro/anti-inflammatory balance in the IL-1 pathway, with lower IL-1 β and IL-6, but
333 higher IL-1Ra response after SARS-CoV-2 stimulation *in vitro*. Baseline levels of inflammatory
334 modulators were mainly correlated with higher anti-inflammatory cytokine production upon SARS-CoV-
335 2 infection *in vitro*. Fast induction of pro-inflammatory cytokines at the beginning of SARS-CoV-2
336 infection is crucial to decrease the viral load (34). However, anti-inflammatory cytokines, such as IL-
337 1Ra, are also necessary to fine-tune the inflammation and counteract excessive inflammation, and it
338 was recently reported to protect against respiratory insufficiency in COVID-19 (35). Together, these
339 cytokines might contribute to keeping a balance in the inflammatory status of the host (36). On the other
340 hand, dysregulation of cytokine responses as during the so-called cytokine storm, is associated with
341 severe disease outcomes (37). Our results indicate that the reprogramming induced by the influenza
342 vaccine could prevent excess inflammation against SARS-CoV-2. We hypothesize that these
343 transcriptomic and proteomic changes induced by influenza vaccination drive immune cells to a distinct
344 functional reprogramming, leading to a balanced response against SARS-CoV-2.

345 A recent study investigated the epigenetic and transcriptional reprogramming as well as cytokine
346 responses of immune cells after a trivalent seasonal influenza vaccine (TIV) and AS03-adjuvanted H5N1

347 influenza vaccine (38). Immunization with TIV led to repressive epigenomic state in myeloid cells. 30
348 days after TIV vaccination, PBMCs produced significantly less TNF α , IL-1 β , IL-12, IP-10, and IL-1RA
349 upon bacterial and viral challenge, in contrast to our observation of enhanced anti-viral response 6
350 weeks after immunization with a quadrivalent influenza vaccine. Both TIV and the AS03-adjuvanted
351 vaccine reduced the expression of AP-1 transcription factors including *FOS* and *JUN* which are highly
352 upregulated in our dataset. On the other hand, the adjuvanted influenza vaccine enhanced the
353 accessibility of anti-viral genes and increased the resistance of PBMCs against Dengue and Zika virus
354 infections. This is another important finding suggesting that heterologous protection can be induced by
355 influenza vaccination. However, it is clear that different types of influenza vaccines, also depending on
356 the adjuvants, induce distinct trained immunity programs.

357 Our study also has important limitations. The hospital population database analysis performed in this
358 study did not allow correction for confounders, as we were not able to access individual characteristics
359 due to hospital privacy policies. A critical possible confounder could be direct patient contact within
360 influenza vaccinated and unvaccinated personnel. However, earlier studies have reported that most
361 SARS-CoV-2 infections in hospital personnel occur in society rather than through patient contact in the
362 hospitals (39-41). Furthermore, there was no information on comorbidities or other exposures outside
363 the hospital environment. While comorbidities are an important factor related to COVID-19 susceptibility
364 and severity, there are no reasons to expect an unequal distribution of comorbidities among influenza
365 vaccinated and unvaccinated personnel for it to cause skewing of the results. Lastly, one cannot rule
366 out healthy-vaccinee bias, which might lead healthier people to better adhere to annual influenza
367 vaccine recommendations. In addition, the *in vivo* trained immunity effect by influenza vaccination had
368 not been studied as part of a placebo-controlled clinical trial, since healthy volunteers, who had decided
369 autonomously to get vaccinated, were recruited.

370 In conclusion, we provide observational data suggesting a negative association between the
371 quadrivalent inactivated influenza vaccine and COVID-19 incidence. Additionally, we report first insights
372 into the immunological mechanisms underlying these observations. We show that seasonal influenza
373 vaccination can induce a distinct trained immunity program by reducing systemic inflammation and
374 regulating the transcriptional program and cytokine production of circulating immune cells. Considering
375 these data, influenza vaccination may contribute not only to a reduction of influenza but also to the
376 COVID-19-related burden on the healthcare system. Our data show that influenza vaccination is safe in

377 relation to a later SARS-CoV-2 infection, and phase III clinical trials to assess its effects on COVID-19
378 are warranted.

379 **4. METHODS**

380 **4.1. Observational study in healthcare workers**

381 Study subjects

382 The Radboudumc databases on influenza vaccination status and COVID-19 incidence among
383 employees were provided by the Department of Occupational Health and Safety. The hospital databases
384 of SARS-CoV-2 PCR-positive healthcare workers during the first (March - June 2020) and the second
385 (November 2020 - January 2021) COVID-19 waves were consulted, and the corresponding influenza
386 vaccination status of employees was retrieved. Given the observational nature of this study, ethical
387 waiver was obtained from the Arnhem-Nijmegen Ethical Committee.

388 Data analysis

389 Hospital database analysis was done using GraphPad Prism 8 (CA, USA). To assess the association
390 between COVID-19 incidence and influenza vaccination status, a Chi-square test was used, and the
391 relative risks (RR) are reported. No correction for confounding was possible because no individual
392 characteristics were available from the databases; only influenza vaccination status and COVID-19
393 history were known. All hospital employees are equally offered an influenza vaccination every year.
394 Vaxigrip Tetra and Influvac Tetra were used during the influenza seasons of 2019/2020 and 2020/2021,
395 respectively. It is important to note that SARS-CoV-2 testing at the beginning of the pandemic was only
396 available for employees who were indispensable for patient care due to a shortage of testing materials.

397

398 **4.2. Ex-vivo study of immune responses following influenza vaccination**

399 Subjects and study design

400 28 healthy volunteers, employees of the University Hospital Duesseldorf, were enrolled in the study.
401 The average age and BMI were 34.9 ± 8.9 and 22.8 ± 2.8 , respectively. 61% of the study participants were
402 female. Participants were vaccinated with 0.5 mL of Influvac Tetra (Abbott Biologicals, IL, USA)
403 intramuscularly.

404 PBMC isolation and stimulation

405 Venous blood was drawn in 3 mL EDTA tubes. The blood was diluted 1:1 with Phosphate Buffered
406 Saline (PBS). Subsequently, PBMCs were isolated using Ficoll-paque (Sigma Aldrich, Taufkirchen,
407 Germany) density gradient centrifugation. The PBMCs layer was collected and washed twice in cold
408 PBS. Cells were reconstituted in RPMI+, consisting of RPMI-1640 culture medium (Sigma Aldrich,
409 Taufkirchen, Germany) supplemented with 10 µg/mL gentamicin, 10 mM L-glutamine and 10 mM
410 pyruvate (Gibco).

411 Stimulations were performed in the presence of 2% human AB serum (Sigma Aldrich, Taufkirchen,
412 Germany) for the 24h-stimulations and 10% human serum for the 7-day-stimulations. Cells were
413 incubated at 37°C with 5% CO₂, after 24 hours or 7 days, respectively, supernatants were collected and
414 stored at -80°C.

415 End-concentration of the stimuli: pathogens and recombinant PAMPs

416 Heat-inactivated Influenza B Brisbane (7,4*10³ K/mL TCID₅₀), heat-inactivated Influenza H1N1
417 California (3,24 x 10⁵ K/mL TCID₅₀), and heat-inactivated SARS-CoV-2 Wuhan-Hu-1 variant (1,4 x
418 10³K/mL TCID₅₀) were used in the study. Viruses had been heat-inactivated for 30 minutes at 60°C.
419 Heat-inactivation had been checked for sufficiency by cell culture inoculation and subsequent qPCR
420 testing. R848 (Resiquimod, TLR7/8 ligand) (Invivogen, San Diego, CA, USA) (3 µg/mL); Poly I:C (TLR3
421 ligand) (Invivogen, San Diego, CA, USA) (10 µg/mL).

422 Cytokine measurements

423 IL-1β, IL-1Ra, IL-10, IFNα, and IL-12p70 were measured in the cell culture supernatants after 24h
424 stimulation using a custom-made multiplex ELISA kit (Procartaplex, Life Technologies GmbH,
425 Darmstadt, Germany) according to the instructions supplied by the manufacturer. IL-6 and TNFα were
426 measured after 24h stimulation and IL-17, IFNγ and IL-22 were measured after 7 days stimulation in the
427 cell culture supernatant using a duo-set ELISA according to the protocol supplied by the manufacturer
428 (R&D systems, Minneapolis. MN, USA). Differences between cytokine productions before and after
429 influenza vaccination were analyzed using the Wilcoxon signed-rank test. All calculations were
430 performed in GraphPad Prism 8. A p-value lower than 0.05 was considered statistically significant.

431 Proteomics measurements and analysis

432 Plasma proteins were measured using the Olink Explore Cardiometabolic, Inflammation, Neurology, and
433 Oncology panels by Olink Proteomics (Uppsala, Sweden). Out of 1472 proteins, 183 had a missing data
434 frequency of 25% and were removed from the analyses. Measurements are denoted as normalized
435 protein expression (NPX) values, which provide relative quantification on a log₂ scale. Principal
436 component analysis (PCA), differential expression analysis, and correlations using Spearman's rank-
437 order correlation were performed in R (version 4.0.3) and R Studio (version 1.3.1093). R package *limma*
438 was used for differential expression analysis and p-values < 0.05 after Benjamini-Hochberg adjustment
439 were considered significant.

440 RNA-sequencing

441 Cryopreserved PBMCs from 10 individuals before and after vaccination were used to perform single cell
442 RNA sequencing. Frozen cells were thawed at 37 °C and counted using an automated cell counter.
443 Equal number of cells (3,300 per individual) from 4 different individuals were pooled together and then
444 loaded into the Chromium™ Controller to separate single cells into Gel Beads-in-emulsion (GEMs).
445 Gene expression libraries were constructed following the standard 10X genomics guides (Chromium
446 Next GEM Single Cell 3' Reagent Kits v3.1 (Dual Index) User Guide, Rev A). Library quality per pool
447 was checked using the Agilent Bioanalyzer High Sensitivity DNA kit. For each pooled library, single-cell
448 RNA sequencing was performed in paired-end mode on NovaSeq 6000 (Illumina) with a depth of 50,000
449 reads per cell. DNA was isolated from PBMCs and then used for genotyping by Illumina GSA Beadchip.

450 Single-cell RNA-sequencing analysis

451 Reads from scRNA-seq data were aligned to GRCh38 genome using *cellranger* (v.4.0.0, 10X Genomics)
452 to generate a count matrix for each pool recording the number of transcripts (UMIs) for each gene in
453 each cell. Next, we demultiplexed and clustered cells within each pool into four samples using
454 *souporcell*, a genotype-free method (42). Then, we matched SNPs called from each demultiplexed-
455 sample to individual genotypes and labeled cells accordingly.

456 After demultiplexing, we used the R package *Seurat* (v4.0.1) for downstream analysis. For quality
457 control, we excluded cells that met the one of the following criteria: mitochondrial content > 25%, either
458 < 100 or > 3000 detected genes per cell, and > 5000 detected transcripts per cell. Furthermore,
459 mitochondrial genes and ribosomal genes were removed from further analyses. Then, gene expression

460 values were normalized by total UMI counts per cell, multiplied by 10,000 (TP10k) and log-transformed
461 by $\log_{10}(\text{TP10k}+1)$.

462 Subsequently, we followed a typical *Seurat* clustering workflow with the following steps: First, we
463 selected the 2,000 most variable features and scaled against the number of UMIs. PCA was performed,
464 followed by Shared Nearest Neighbor (SNN) Graph construction using PC1 through PC20 to identify
465 cell clusters. Finally, Uniform Manifold Approximation and Projection (UMAP) was used to visualize the
466 cell clusters. Cell type annotation was based on the following canonical gene markers and combined
467 with SingleR (43) unsupervised annotation results: Naïve CD4+ T (IL7R, TCF7, CCR7), Memory CD4+
468 T (IL7R), CD8+ T (CD8A, CD8B, NKG7), NK (GZMB, NKG7, GNLY), CD14+ Monocytes (CD14, LYZ),
469 CD16+ Monocytes (FCGR3A), B (CD79A, MS4A1), DC (IRF8, TCF4), megakaryocytes (PPBP)

470 Differential expression and enrichment analyses in scRNAseq

471 Differential expression analysis was performed in *Seurat* using *FindMarkers* using the Wilcoxon rank
472 sum test. Genes were considered differentially expressed if they were expressed in at least 10% in
473 either tested group, and the p-value after Bonferroni post-hoc correction was < 0.05 . Significantly
474 differentially expressed genes between the conditions were retrieved per cell type and used as input for
475 GO enrichment using *ClusterProfiler* (v.3.18.1) (44). Enrichment of genes was tested both in Gene
476 Ontologies (GO) and within the Kyoto Encyclopedia of Genes and Genomes (KEGG) and considered
477 significant if the Benjamini-Hochberg adjusted p-value was < 0.05 .

478 Study Approval

479 Ethical approval was obtained from the Duesseldorf Ethical Committee (study ID 2018_199, amendment
480 2018-199_1- (5/2020), and amendment 2018_199_2 (12/2020)) for the ex vivo study investigating
481 immune responses after influenza vaccination. After giving written informed consent, blood was
482 collected by venous blood puncture 1 week before and 6 weeks after vaccination. All experiments were
483 conducted in accordance with the Declaration of Helsinki. No adverse events were recorded.

484 **AUTHOR CONTRIBUTIONS**

485 PAD, KLG, and MGN designed the studies. PAD, SJCFMM, ET, PS conducted the observational study.
486 LM and PNO performed the virus heat-inactivation. MO, NR and KLG conducted the ex-vivo
487 immunological experiments. ZL performed the scRNAseq experiments. PAD, KLG, OB, GK, VACMK,
488 MZ, BZ, CX, and YL performed the analyses. PAD, KLG, OB, GK, HS, PS, JtO, JDA, RvC, and MGN
489 conceptualized the manuscript. All co-authors provided input on draft versions and approved the final
490 version.

491

492 **ACKNOWLEDGMENTS**

493 MGN was supported by a Spinoza Grant of the Netherlands Association for Scientific Research and an
494 ERC Advanced Grant (#833247). YL was supported by an ERC Starting Grant (#948207) and a
495 Radboud University Medical Centre Hypatia Grant (2018). PNO, LM and HS were supported by the
496 Jürgen Manchot Foundation. KLG was supported by the German Research Foundation (DFG #
497 428917761). MO was supported by the Research Committee of the Heinrich Heine University
498 Duesseldorf. We thank the Department of Occupational Health and Safety (Radboud University Medical
499 Center, Nijmegen) for providing Influvac Tetra®.

500

501 **DECLARATION OF INTERESTS**

502 The authors declare no competing interests.

REFERENCES

- 503 1. WHO. World health organisation, COVID-19 dashboard 2020 [Available from: <https://covid19.who.int/>.
504 2. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99
505 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet*. 2020;395(10223):507-
506 13.
507 3. Chen WH, Strych U, Hotez PJ, Bottazzi ME. The SARS-CoV-2 Vaccine Pipeline: an Overview. *Curr Trop*
508 *Med Rep*. 2020:1-4.
509 4. Thanh Le T, Andreadakis Z, Kumar A, Gómez Román R, Tollefsen S, Saville M, et al. The COVID-19
510 vaccine development landscape. *Nat Rev Drug Discov*. 2020;19(5):305-6.
511 5. Wouters OJ, Shadlen KC, Salcher-Konrad M, Pollard AJ, Larson HJ, Teerawattananon Y, et al.
512 Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment.
513 *Lancet*. 2021;397(10278):1023-34.
514 6. Garcia-Beltran WF, Lam EC, St Denis K, Nitido AD, Garcia ZH, Hauser BM, et al. Multiple SARS-CoV-2
515 variants escape neutralization by vaccine-induced humoral immunity. *Cell*. 2021.
516 7. Netea MG, Giamarellos-Bourboulis EJ, Dominguez-Andres J, Curtis N, van Crevel R, van de Veerdonk
517 FL, et al. Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection. *Cell*.
518 2020;181(5):969-77.
519 8. Netea MG, Dominguez-Andres J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, et al. Defining trained
520 immunity and its role in health and disease. *Nat Rev Immunol*. 2020;20(6):375-88.
521 9. Pawlowski C, Puranik A. Exploratory analysis of immunization records highlights decreased SARS-CoV-
522 2 rates in individuals with recent non-COVID-19 vaccinations. 2020;2020.
523 10. Amato M, Werba JP, Frigerio B, Coggi D, Sansaro D, Ravani A, et al. Relationship between Influenza
524 Vaccination Coverage Rate and COVID-19 Outbreak: An Italian Ecological Study. *Vaccines (Basel)*. 2020;8(3).
525 11. Conlon A, Ashur C, Washer L, Eagle KA, Hofmann Bowman MA. Impact of the influenza vaccine on
526 COVID-19 infection rates and severity. *Am J Infect Control*. 2021.
527 12. Fink G, Orlova-Fink N, Schindler T, Grisi S, Ferrer APS, Daubenberger C, et al. Inactivated trivalent
528 influenza vaccination is associated with lower mortality among patients with COVID-19 in Brazil. *BMJ Evid Based*
529 *Med*. 2020.
530 13. Lisewski, Martin A. Association between Influenza Vaccination Rates and SARS-CoV-2 Outbreak
531 Infection Rates in OECD Countries. SSRN. 2020.
532 14. consortium E. COVID-19 Severity in Europe and the USA: Could the seasonal influenza vaccination play
533 a role? SSRN. 2020.

- 534 15. Marin-Hernandez D, Schwartz RE, Nixon DF. Epidemiological evidence for association between higher
535 influenza vaccine uptake in the elderly and lower COVID-19 deaths in Italy. *J Med Virol*. 2020.
- 536 16. Zanettini C, Omar M, Dinalankara W, Imada EL, Colantuoni E, Parmigiani G, et al. Influenza Vaccination
537 and COVID19 Mortality in the USA. *medRxiv*. 2020.
- 538 17. Arokiaraj MC. Correlation of Influenza Vaccination and Influenza Incidence on COVID-19 Severity and
539 Other Perspectives. 2020.
- 540 18. Fink G, Orlova-Fink N. Inactivated Trivalent influenza vaccien is associated with lower mortality among
541 Covid-19 patients in Brazil. *medRxiv*. 2020.
- 542 19. Yang MJ, Rooks BJ, Le TT, Santiago IO, 3rd, Diamond J, Dorsey NL, et al. Influenza Vaccination and
543 Hospitalizations Among COVID-19 Infected Adults. *J Am Board Fam Med*. 2021;34(Suppl):S179-S82.
- 544 20. Jehi L, Ji X, Milinovich A, Erzurum S, Rubin BP, Gordon S, et al. Individualizing Risk Prediction for
545 Positive Coronavirus Disease 2019 Testing: Results From 11,672 Patients. *Chest*. 2020;158(4):1364-75.
- 546 21. Blok BA, Arts RJ, van Crevel R, Benn CS, Netea MG. Trained innate immunity as underlying mechanism
547 for the long-term, nonspecific effects of vaccines. *J Leukoc Biol*. 2015;98(3):347-56.
- 548 22. Briggs RC, Briggs JA, Ozer J, Sealy L, Dworkin LL, Kingsmore SF, et al. The human myeloid cell nuclear
549 differentiation antigen gene is one of at least two related interferon-inducible genes located on chromosome 1q
550 that are expressed specifically in hematopoietic cells. *Blood*. 1994;83(8):2153-62.
- 551 23. Riese RJ, Mitchell RN, Villadangos JA, Shi GP, Palmer JT, Karp ER, et al. Cathepsin S activity regulates
552 antigen presentation and immunity. *J Clin Invest*. 1998;101(11):2351-63.
- 553 24. Ou X, Liu Y, Lei X, Li P, Mi D, Ren L, et al. Characterization of spike glycoprotein of SARS-CoV-2 on
554 virus entry and its immune cross-reactivity with SARS-CoV. *Nat Commun*. 2020;11(1):1620.
- 555 25. Bosso M, Prelli Bozzo C, Hotter D, Volcic M, Sturzel CM, Rammelt A, et al. Nuclear PYHIN proteins
556 target the host transcription factor Sp1 thereby restricting HIV-1 in human macrophages and CD4+ T cells. *PLoS*
557 *Pathog*. 2020;16(8):e1008752.
- 558 26. Imamura K, Imamachi N, Akizuki G, Kumakura M, Kawaguchi A, Nagata K, et al. Long noncoding RNA
559 NEAT1-dependent SFPQ relocation from promoter region to paraspeckle mediates IL8 expression upon immune
560 stimuli. *Mol Cell*. 2014;53(3):393-406.
- 561 27. Zhou Q, Run Q, Li CY, Xiong XY, Wu XL. LncRNA MALAT1 Promotes STAT3-Mediated Endothelial
562 Inflammation by Counteracting the Function of miR-590. *Cytogenet Genome Res*. 2020;160(10):565-78.
- 563 28. Mechta-Grigoriou F, Gerald D, Yaniv M. The mammalian Jun proteins: redundancy and specificity.
564 *Oncogene*. 2001;20(19):2378-89.
- 565 29. Liu T, Zhang L, Joo D, Sun SC. NF-kappaB signaling in inflammation. *Signal Transduct Target Ther*.
566 2017;2.

- 567 30. Koeken VA, de Bree LCJ, Mourits VP, Moorlag SJ, Walk J, Cirovic B, et al. BCG vaccination in humans
568 inhibits systemic inflammation in a sex-dependent manner. *J Clin Invest*. 2020;130(10):5591-602.
- 569 31. Nakamura S, Horie M, Daidoji T, Honda T, Yasugi M, Kuno A, et al. Influenza A Virus-Induced
570 Expression of a GalNAc Transferase, GALNT3, via MicroRNAs Is Required for Enhanced Viral Replication. *J*
571 *Viro*. 2016;90(4):1788-801.
- 572 32. Li S, Zhang Y, Guan Z, Li H, Ye M, Chen X, et al. SARS-CoV-2 triggers inflammatory responses and cell
573 death through caspase-8 activation. *Signal Transduct Target Ther*. 2020;5(1):235.
- 574 33. Pereira B, Xu XN, Akbar AN. Targeting Inflammation and Immunosenescence to Improve Vaccine
575 Responses in the Elderly. *Front Immunol*. 2020;11:583019.
- 576 34. Xie C, Li Q, Li L, Peng X, Ling Z, Xiao B, et al. Association of Early Inflammation with Age and
577 Asymptomatic Disease in COVID-19. *J Inflamm Res*. 2021;14:1207-16.
- 578 35. Kyriazopoulou E, Poulakou G, Milionis H, Metallidis S, Adamis G, Tsiakos K, et al. Early Anakinra
579 Treatment for COVID-19 Guided by Urokinase Plasminogen Receptor. 2021:2021.05.16.21257283.
- 580 36. Moorlag S, Roring RJ, Joosten LAB, Netea MG. The role of the interleukin-1 family in trained immunity.
581 *Immunol Rev*. 2018;281(1):28-39.
- 582 37. Hojyo S, Uchida M, Tanaka K, Hasebe R, Tanaka Y, Murakami M, et al. How COVID-19 induces
583 cytokine storm with high mortality. *Inflamm Regen*. 2020;40:37.
- 584 38. Wimmers F, Donato M, Kuo A, Ashuach T, Gupta S, Li C, et al. The single-cell epigenomic and
585 transcriptional landscape of immunity to influenza vaccination. *Cell*. 2021.
- 586 39. Rhee C, Baker M, Vaidya V, Tucker R, Resnick A, Morris CA, et al. Incidence of Nosocomial COVID-19
587 in Patients Hospitalized at a Large US Academic Medical Center. *JAMA Netw Open*. 2020;3(9):e2020498.
- 588 40. Rickman HM, Rampling T, Shaw K, Martinez-Garcia G, Hail L, Coen P, et al. Nosocomial transmission of
589 COVID-19: a retrospective study of 66 hospital-acquired cases in a London teaching hospital. *Clin Infect Dis*.
590 2020.
- 591 41. Wake RM, Morgan M, Choi J, Winn S. Reducing nosocomial transmission of COVID-19: implementation
592 of a COVID-19 triage system. *Clin Med (Lond)*. 2020;20(5):e141-e5.
- 593 42. Heaton H, Talman AM, Knights A, Imaz M, Gaffney DJ, Durbin R, et al. Souporecell: robust clustering of
594 single-cell RNA-seq data by genotype without reference genotypes. *Nat Methods*. 2020;17(6):615-20.
- 595 43. Aran D, Looney AP, Liu L, Wu E, Fong V, Hsu A, et al. Reference-based analysis of lung single-cell
596 sequencing reveals a transitional profibrotic macrophage. *Nat Immunol*. 2019;20(2):163-72.
- 597 44. Yu G, Wang LG, Han Y, He QY. clusterProfiler: an R package for comparing biological themes among
598 gene clusters. *OMICS*. 2012;16(5):284-7.

Observational Study

Seasonal influenza
vaccination



Hospital Employees



Reduced COVID-19 incidence

37% during the
first wave
(n=6856)

49% during the
second wave
(n=10899)

Clinical Study


Influenza
vaccination



Healthy cohort
(n=28)



In vitro SARS-CoV-2
stimulation




PBMCs

↓ IL-6, IL-1 β
↑ IL-1RA



↓ Systemic
inflammation



↑ Antigen
presentation